News Wire

The FDA has approved Botox (onabotulinumtoxinA, Allergan) for the treatment of lower limb spasticity in adults to reduce the severity of increased stiffness in ankle and toe muscles. Botox is the only botulinum toxin product to be cleared by the FDA for the treatment of multiple muscle groups of the…
Once the realm of science fiction, telemedicine has become a reality of health care –– and an option for patients who might once have been difficult to reach, according to an article posted on the HealthLeaders Media website. San Francisco-based Dignity Health, for example, performed 12,000 telemedicine…
The FDA has approved a supplemental new drug application (sNDA) to update the label for dalbavancin (Dalvance, Allergan) for injection. The expanded label will include a single dose administered as a 30-minute intravenous infusion of dalbavancin for the treatment of acute bacterial skin and skin-structure…
It is well recognized that stress can lead to episodes of depressive illness and that some depressed patients have elevated levels of the stress hormone cortisol as an indication of their mental health. A study conducted at Newcastle University in the United Kingdom has shown that a drug that blocks…
Days after a phase 1 clinical trial studying an experimental fatty acid amide hydrolase (FAAH) inhibitor being developed by the Portuguese company Bial-Portela left one patient dead and five others hospitalized in France, numerous questions remain unanswered, according to an article on the BioSpace…
Martin Shkreli, the former drug company CEO charged with securities fraud, has been subpoenaed by a U.S. congressional committee investigating the price of drugs, according to a report from BloombergBusiness. The House Committee on Oversight and Government Reform will hold a hearing on January 26 to…
Drug manufacturers have unconscionably high profit margins, and the industry must rein in some of its more excessive practices, Catherine DeAngelis, MD, the retired editor-in-chief of JAMA, argues in an editorial published in the Milbank Quarterly. “Big Pharma has crossed the line from reasonable…
David Ross is a violence intervention specialist at the University of Maryland Medical Center. His team works with patients who are victims of violent injuries — stabbings, gunshots, or physical assaults — and who physicians flag as candidates for the program’s assistance. His challenge is to…
When quality improvement organizations (QIOs) took over the role of education and enforcement for the two-midnight rule on October 1, 2015, many anticipated that the reviews would only look at records from that date forward. But some hospitals have reported QIO records requests zeroing in on cases as…
The FDA has approved a supplemental biologics license application for the use of ofatumumab (Arzerra, Genmab/Novartis) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). The approval…
Positive efficacy findings have been reported from the bestPWS ZAF-311 study, a pivotal phase 3, double-blind, placebo-controlled trial evaluating the safety and efficacy of beloranib (Zafgen, Inc.), a MetAP2 inhibitor, in patients with Prader–Willi syndrome (PWS) during a six-month randomized treatment…
The FDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adults with two new indications: active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are life-long painful and debilitating inflammatory diseases that affect the joints and/or spine. If not treated…
A new drug application (NDA) has been submitted to the FDA for the approval of oral once-daily baricitinib (Eli Lilly/Incite Corporation) for the treatment of moderately to severely active rheumatoid arthritis (RA). Baricitinib is the only once-daily oral selective Janus kinase-1 (JAK1) and JAK2 inhibitor…
Reducing excessive medical costs associated with high hospital readmission rates is a pillar of health care reform. From 2007 to 2011, as many as 19% of patients in the U.S. returned to hospitals less than a month after discharge, accounting for an estimated $15 million in preventable hospitalization…
Better coordination between hospitals and post-acute care facilities could reduce patient readmission to hospitals and mortality rates, according to a new study of risk factors conducted by researchers at the University of Colorado’s Anschutz School of Medicine. In a review of more than 3,200 hospitalizations…

Pages